A naukri.com initiative
Bioengineer
2w
393
Image Credit: Bioengineer
Rivaroxaban Proves Safe and Effective for Extended Use in Treating Venous Thromboembolism in Children
- Venous thromboembolism (VTE) in pediatric populations presents significant challenges, especially in children with serious underlying medical conditions like congenital heart defects or malignancies.
- Historically, pediatric VTE has been under-investigated, resulting in gaps in evidence-based treatment protocols for children compared to adults.
- Traditional anticoagulants for children, such as heparin and warfarin, have limitations like parenteral administration and requiring frequent monitoring.
- Rivaroxaban, a direct oral anticoagulant, has emerged as a promising option for pediatric VTE treatment, eliminating the need for routine monitoring.
- Rivaroxaban's efficacy and safety in children with acute VTE match or exceed standard anticoagulants, leading to global regulatory approvals for pediatric use in 2021.
- A recent study analyzed extended-phase rivaroxaban treatment in nearly 500 children, demonstrating its well-tolerated nature and low incidence of adverse events.
- The pediatric-tailored rivaroxaban regimen simplifies dosing, reduces clinic visits, and offers improved adherence, positively impacting treatment outcomes.
- Rivaroxaban's targeted inhibition of factor Xa minimizes bleeding risk compared to traditional anticoagulants, emphasizing its safety and potency in pediatric patients.
- This research sets a new standard for pediatric VTE management, providing a scientifically validated, age-appropriate oral anticoagulant option for children.
- The study underscores the importance of age-appropriate drug development and international collaboration in improving therapeutic options for vulnerable pediatric populations.
Read Full Article
23 Likes
For uninterrupted reading, download the app